Newsbenzinga
Nasus Pharma Says FDA Cleared IND Application For NS002 Intranasal Epinephrine Powder In Anaphylaxis; Plans Pivotal Study In Q4 2026, Topline Data In Q1 2027
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…